This dual-target combination therapy can block the tumor-driving effect of TGF-β1 and overcome the immune escape induced by TGF-β1 (33), which provides more suitable conditions for the binding of monoclonal antibodies and PD-L1. This evidence concerns the gene TGFB1 and neoplasm.